SCHEMBL15066680

SCHEMBL15066680

Cc1cn2cc(-c3cc4ccccc4oc3=O)nc2cn1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.71
NPC1 O15118 8/20 0.71
ALDH1A1 P00352 8/20 0.71
MAPT P10636 5/20 0.71
POLB P06746 1/20 0.71
NFKB1 P19838 1/20 0.71
NFKB2 Q00653 1/20 0.71
RELA Q04206 1/20 0.71
LMNA P02545 2/20 0.66
PKM P14618 1/20 0.66
KDM4E B2RXH2 7/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
TP53 P04637 6/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
HPGD P15428 4/20 0.59
HSD17B10 Q99714 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GAA P10253 1/20 0.59
TSHR P16473 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15065770 0.81 RAB9A (0.67) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15068705 0.81 RAB9A (0.73) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15068605 0.80 NPC1 (0.48) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL4726437 0.79 RAB9A (0.71) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15069138 0.79 NPC1 (0.46) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15067367 0.79 NPC1 (0.46) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL16669038 0.78 RAB9A (0.69) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15069105 0.78 NPC1 (0.45) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15066012 0.77 NPC1 (0.45) RAB9ANPC1ALDH1A1MAPTPOLB
SCHEMBL15068923 0.77 NPC1 (0.45) RAB9ANPC1ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE47689-E1 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2019-11-05 US disclosed
US-9617268-B2 Compounds for treating spinal muscular atrophy PTC THERAPEUTICS, INC. (US) 2017-04-11 US disclosed
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-30 US disclosed
EP-2797592-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC Therapeutics, Inc. (US) 2014-11-05 EP disclosed
WO-2013101974-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY PTC THERAPEUTICS, INC. (US) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119380-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY SMN1; SMN2, RBM17, RBM22 RAB9A 3292/4885NPC1 4329/4885ALDH1A1 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.